STOCK TITAN

Integra LifeSciences Holdings (IART) 10-K Filings

IART NASDAQ

Here are the 10-K annual reports from Integra LifeSciences Holdings (IART) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow IART and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IART filings page.

Rhea-AI Summary

Integra LifeSciences Holdings Corporation files its Annual Report describing a global medical technology business focused on neurosurgery, surgical instruments, ENT and regenerative tissue products. The Codman Specialty Surgical segment provides about 70% of revenue, with Tissue Technologies contributing about 30%.

The company highlights its leadership in neurosurgery, advanced wound care and soft-tissue reconstruction, supported by a broad R&D program and global sales network. It is pursuing PMA approvals for SurgiMend and DuraSorb in breast reconstruction, targeted for 2026, and is relocating and expanding manufacturing capacity, including a new Braintree, Massachusetts facility.

Integra outlines extensive quality and regulatory initiatives, including a Compliance Master Plan to upgrade its quality management systems and respond to FDA expectations. The report also details competitive dynamics, reimbursement and healthcare reform pressures, and comprehensive global regulatory and data privacy obligations. As of June 30, 2025, non‑affiliate market value was about $925.1 million, with 77,937,208 common shares outstanding as of February 25, 2026.